...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

** BETonMACE Phase 3 Cardio Outcomes Trial for Apabetalone Has Reached its Targeted 250 MACE Events ** Top-Line Data Expected Mid-Year 2019 https://clinicaltrials.gov/ct2/show/NCT02586155

Message: The positive view

A very brief comment but the positive take on this is that it removes the overhang of Dart taking control of thr IP. From memory I believe the IP was pledged as collateral for the loan. It is depressing that we are being diluted at this valuation but at least one of the severe adverse scenarios is off the table. This company, however,  is a case study in how not to run a start up biotech. I believe DM has straight intentions but we have suffered due to his inexperience and naivety. I like him but he should not be leading this company.

New Message
Please login to post a reply